HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma

BackgroundAs a recognized highly immunogenic tumor, immune checkpoint blockades (ICB) have been widely used as a systemic treatment option for melanoma. However, only about half of treated patients could benefit from it in Caucasians, and only about 15% in Chinese melanoma patients. Robust predictiv...

Full description

Bibliographic Details

Published in:	Frontiers in Immunology
Main Authors:	Fu-xue Huang, Jun-wan Wu, Xia-qin Cheng, Jiu-hong Wang, Xi-zhi Wen, Jing-jing Li, Qiong Zhang, Hang Jiang, Qiu-yue Ding, Xiao-feng Zhu, Xiao-shi Zhang, Ya Ding, Dan-dan Li
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-08-01
Subjects:	melanoma HHLA2 immunotherapy prognosis tumor infiltrating lymphocytes
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2022.902167/full